This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF17 / Rho guanine nucleotide exchange factor 17 · IHC design guide
Design Immunohistochemistry for ARHGEF17
Plan ARHGEF17 IHC-P using heart cardiomyocytes as a high-staining reference (HPA tissue IHC). Start the human-reactive catalog antibody at 2.5 μg/mL (datasheet: IHC-P), and interpret the cytoplasmic pattern with HPA’s uncertain tissue-IHC reliability in mind (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF17 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining across many tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Appendix+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining–RNA consistency is medium (HPA tissue IHC) | |
| Regulation | No expression regulator reported (UniProt) | |
| Isoform / epitope | No isoforms; one 1–2063 chain annotated (UniProt) |
Section 1
Recommended ARHGEF17 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published ARHGEF17 staining of ccRCC tissue arrays and colorectal tumor sections (PMC12008239; PMC12775562).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10510); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARHGEF17, 2.5 μg/mL (datasheet A10510) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF17-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate HIER at pH 6.0, 95–98 °C for 20 min (page antigen retrieval); EDTA pH 9.0 is the published colorectal protocol (PMC12775562).
Section 2
What Is the Expected ARHGEF17 Staining Pattern?
Expect predominantly cytoplasmic ARHGEF17 staining in many tissues, with high staining reported in heart cardiomyocytes, adrenal glandular cells, and several glial populations (HPA tissue IHC). Cytosol is the main location in ICC-IF, with additional plasma membrane localization (HPA subcellular). ARHGEF17 has no transmembrane segment (UniProt Q96PE2 topology). Treat tissue patterns as provisional: HPA rates tissue IHC reliability Uncertain, pending external verification (HPA tissue IHC).
| Clear cytoplasmic staining in cardiomyocytes, with limited background in nearby unstained areas (HPA: High in heart cardiomyocytes). | This matches a reported high-staining cell population and the broad cytoplasmic tissue profile (HPA tissue IHC). Compare it with a low- or undetected-staining reference on the same run; HPA's Uncertain reliability means appearance alone does not establish antibody specificity (HPA tissue IHC; standard IHC practice). |
| Predominantly nuclear or extracellular staining replaces the expected cytoplasmic pattern (HPA tissue IHC). | Treat this as a possible staining artefact and review morphology and controls (standard IHC practice). HPA reports cytoplasmic tissue staining and mainly cytosolic ICC-IF localization, with additional plasma membrane localization; those observations do not validate a dominant nuclear or extracellular IHC pattern (HPA tissue IHC; HPA subcellular). |
| Strong staining appears in appendix glandular cells or bone marrow hematopoietic cells (HPA: Not detected in those cells). | Consider antibody cross-reactivity or endogenous detection activity, especially if control sections also develop color (standard IHC practice). HPA's Not detected calls describe its observations, not proof that every specimen or assay must be negative (HPA tissue IHC: Uncertain). |
| Color spreads across tissue and cell-free areas, obscuring cell boundaries (standard IHC practice). | Interpret the pattern cautiously because background can obscure the cytoplasmic distribution used for comparison with HPA (HPA tissue IHC; standard IHC practice). Check the no-primary control and detection background before scoring cell populations (standard IHC practice). |
| No staining is visible in heart cardiomyocytes despite preserved morphology (HPA: High in heart cardiomyocytes). | First consider a failed staining run or insufficient assay sensitivity, then assess whether this specimen differs from the HPA reference (standard IHC practice; HPA tissue IHC). A single blank section cannot establish ARHGEF17 absence, particularly given HPA's Uncertain tissue IHC reliability (HPA tissue IHC). |
💡Expected ARHGEF17 appearanceA convincing positive is cell-associated, predominantly cytoplasmic staining in an HPA-high population such as heart cardiomyocytes, with visibly stronger signal than background; dominant nuclear or diffuse cell-free color is suspicious (HPA tissue IHC; standard IHC practice).
| Choice of comparison cells | HPA reports High staining in cardiomyocytes, adrenal glandular cells, several glial populations, cerebellar granular-layer cells, epididymal glandular cells, and cholangiocytes (HPA tissue IHC). It reports Not detected in appendix glandular cells and bone marrow hematopoietic cells, among others; use these as reference patterns, subject to HPA's Uncertain reliability (HPA tissue IHC). |
| Antibody validation | HPA007991 is rated Uncertain for IHC, while HPA074658 has no IHC status in the supplied record (HPA antibodies). The tissue profile has medium consistency with RNA expression and awaits external verification, so matching its pattern supports interpretation but does not independently prove specificity (HPA tissue IHC). |
| Localization and topology | The tissue profile describes cytoplasmic expression in most tissues (HPA tissue IHC). ICC-IF places ARHGEF17 mainly in the cytosol and additionally at the plasma membrane (HPA subcellular). UniProt lists no transmembrane segment or signal sequence; it supplies no subcellular-location annotation (UniProt Q96PE2). |
| What should IF/ICC show? | Mainly cytosolic signal, potentially with plasma membrane signal, is the reported ICC-IF pattern (HPA subcellular: Approved). Both listed antibodies have Approved ICC status (HPA antibodies). This observation informs compartment checks but does not establish that a membrane rim must be visible in chromogenic tissue IHC (HPA subcellular; standard IHC practice). |
| Retrieval and fixation sensitivity | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| Situation | Likely cause | Next action |
|---|---|---|
| Heart reference section is blank (HPA: High in heart cardiomyocytes). | Primary antibody, detection, or retrieval may have failed; the individual specimen may also differ from the HPA reference (standard IHC practice; HPA tissue IHC). | Check the run's positive and no-primary controls, reagent sequence, and the antibody's applicable IHC instructions; repeat before calling the sample negative (standard IHC practice). |
| Signal is mostly nuclear rather than cytoplasmic (HPA tissue IHC). | Nonspecific staining or interpretation of counterstain may be responsible (standard IHC practice). Predominant nuclear localization is not the supplied HPA pattern (HPA tissue IHC; HPA subcellular). | Compare chromogen with counterstain and no-primary controls, then review cellular boundaries and antibody conditions (standard IHC practice). |
| Appendix glandular cells stain strongly (HPA: Not detected). | Possible cross-reactivity or endogenous detection activity; HPA's tissue calls are Uncertain and do not establish an absolute negative control (standard IHC practice; HPA tissue IHC). | Inspect a no-primary control and a separate HPA-high reference, and reassess whether the staining is cell-associated and cytoplasmic (standard IHC practice; HPA tissue IHC). |
| Broad haze obscures cell boundaries (standard IHC practice). | Insufficient blocking or washing, or excessive primary or detection reagent, can raise background (standard IHC practice). | Review no-primary background, blocking, washes, and antibody and detection conditions; judge the result only once cell-associated staining can be distinguished (standard IHC practice). |
| Color appears without primary antibody (standard IHC practice). | Endogenous detection activity or detection-reagent background may contribute signal independent of primary-antibody binding (standard IHC practice). | Address the relevant endogenous activity for the chosen chromogenic system and repeat the no-primary control before scoring ARHGEF17 (standard IHC practice). |
| Staining varies across sections from the same run (standard IHC practice). | Uneven reagent coverage or inconsistent processing can produce technical variation (standard IHC practice); HPA's Uncertain rating also limits confidence in a single reference pattern (HPA tissue IHC). | Check section coverage, run records, and controls, then compare like cell populations across interpretable sections (standard IHC practice; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing ARHGEF17 staining
A10510 · IHCImmunohistochemistry of TEM4 in human spleen tissue with TEM4 antibody at 2.5 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/cerebral+cortex#imid_2791328
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/colon#imid_2791246
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/liver#imid_2791247
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/kidney#imid_2791256
HPA · ICC-IF CACO-2Human Protein Atlas immunofluorescence, CACO-2, antibody HPA074658; green = ARHGEF17, blue = nucleus, red = microtubules.
HPA · ICC-IF CACO-2Human Protein Atlas immunofluorescence, CACO-2, antibody HPA074658; green = ARHGEF17, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF17 IHC & IF
🧪Run adrenal gland first: glandular cells should stain strongly (HPA: High in adrenal gland glandular cells); use appendix glandular cells as the negative tissue (HPA: Not detected in appendix glandular cells). On the adrenal slide, assess other cell types against the no-primary background without assuming they are negative, since the supplied HPA row specifies glandular cells only (HPA: adrenal gland glandular cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Appendix (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF17 in CACO-2, Rh30, SK-MEL-30, A-431, U-251MG, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include no-primary/secondary-only and host-species- and clonality-matched isotype controls, plus a knockout specimen or peptide-block control if available (standard IHC practice). For chromogenic detection, quench endogenous peroxidase and check for endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window and the effect of fixation are unreported in the supplied evidence; the selected A10510 spleen IHC caption also leaves the fixative unreported (A10510 tissue-IHC caption). Retrieval dependence is unreported, so optimize antigen retrieval on the chosen paraffin sections (standard IHC practice). The evidence does not establish whether frozen sections or IF are easier for ARHGEF17; assess tissue background during optimization, including any endogenous pigment that could obscure chromogenic staining (standard IHC practice).
HPA tissue IHC evidence for ARHGEF17
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Rectum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF17 IHC Tips
Troubleshoot ARHGEF17 staining in paraffin-section chromogenic IHC, with a separate note on translating localization checks to IF/ICC.
How should I optimize retrieval when ARHGEF17 staining is weak?
Begin with citrate pH 6.0 heat-induced retrieval at 95–98 °C for 20 min (page retrieval rule for this cytoplasmic / membrane antigen). Compare sections from the same block with and without retrieval, keeping antibody concentration and chromogen development constant so changes are interpretable. If staining remains weak, test a more alkaline retrieval buffer as a fallback, while watching for tissue damage and increased background (standard IHC practice). Use cardiomyocytes as a positive-reference cell population (HPA tissue IHC: High in heart muscle cardiomyocytes), and record both staining intensity and preservation of cellular detail.
Could fixation explain variable ARHGEF17 staining between paraffin blocks?
Target-specific sensitivity to fixation is unknown: the selected tissue-IHC caption does not state a fixative (A10510 tissue-IHC caption). Compare blocks with documented processing histories, then stain sections together using the same citrate pH 6.0, 95–98 °C, 20 min retrieval schedule (page retrieval rule). If processing histories differ, interpret weaker staining cautiously; fixative exposure and subsequent processing can affect antigen accessibility in paraffin-section IHC (standard IHC practice). Include a consistent positive-reference section in each run and compare tissue morphology, counterstain, and staining distribution before attributing differences to ARHGEF17 expression.
Which staining compartment should I accept as plausible for ARHGEF17?
Look primarily for cytoplasmic staining in tissue sections (HPA tissue IHC: cytoplasmic expression in most tissues). Cytosolic signal, with possible plasma-membrane enrichment, is consistent with the approved IF localization (HPA subcellular: cytosol and plasma membrane), but that IF observation does not independently validate a tissue-IHC pattern. ARHGEF17 has no annotated transmembrane segment (UniProt Q96PE2 topology), so assess apparent membrane staining against neighboring cytoplasm and section edges before assigning it to the protein. Score diffuse nuclear-only staining separately as unexpected, and compare it with the negative-reagent control and a positive-reference cell population (HPA tissue IHC: High in heart muscle cardiomyocytes).
How do epitope uncertainty and phosphorylation affect my IHC controls?
The supplied record lists 0 isoforms and a DH domain at residues 1066–1254 (UniProt Q96PE2 record); neither identifies the catalog antibody’s epitope. ARHGEF17 also has annotated phosphoresidues, including serines 142 and 152 (UniProt Q96PE2 modified residues), but an effect on this antibody cannot be inferred without its epitope information. Request the immunogen or epitope specification before interpreting loss of staining after a change in processing or biological condition. For IHC, compare matched sections, a positive-reference population, and an independent antibody if available; document agreement in cell type and compartment rather than assuming identical epitopes.
How can IF/ICC help check an ARHGEF17 IHC pattern?
Use IF/ICC as a separate localization check, pairing ARHGEF17 with a marker for the expected cell type; cardiomyocytes are one tissue-based reference population (HPA tissue IHC: High in heart muscle cardiomyocytes). Choose spectrally separated fluorophores and favor a longer-wavelength channel for the weaker signal when tissue autofluorescence interferes (standard IF practice). Permeabilize to assess the cytosolic pool, and compare with a gentler condition if testing membrane-adjacent signal; epitope orientation is unspecified (HPA subcellular: cytosol and plasma membrane; UniProt Q96PE2 topology: no transmembrane segment). Include single-stain and secondary-only controls before comparing IF localization with the chromogenic IHC pattern.
What should I check when ARHGEF17 staining appears widespread?
First compare the pattern with a no-primary control and inspect whether color follows tissue edges, folds, pigment, or damaged regions (standard IHC practice). In chromogenic detection, use an appropriate peroxidase block and examine an antibody-omission section to identify endogenous enzyme signal (standard IHC practice). Titrate the primary antibody and shorten chromogen development if diffuse color obscures cells; the selected spleen image used 2.5 µg/mL, which is an image condition rather than a universal working concentration (A10510 tissue-IHC caption). Widespread cytoplasmic staining can be plausible (HPA tissue IHC: cytoplasmic expression in most tissues), so judge background against controls and cellular detail.
How should I quantify ARHGEF17 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, since tissue IHC describes predominantly cytoplasmic expression (HPA tissue IHC: cytoplasmic expression in most tissues). For comparable regions, report the percentage of positive cells and an H-score based on intensity categories 0–3, or count positive cells per mm² when cellular density is the relevant endpoint (standard IHC scoring practice). Normalize cell-based results to the number of evaluable cells of the specified type, and area-based results to analyzable tissue area. Keep retrieval, antibody exposure, chromogen development, imaging, and threshold rules consistent across sections; exclude folds and necrotic areas using predefined criteria.
When is an apparent ARHGEF17-positive cell likely an artefact?
Expect a predominantly cytoplasmic pattern, with possible membrane-adjacent signal (HPA tissue IHC: cytoplasmic expression in most tissues; HPA subcellular: cytosol and plasma membrane). Treat isolated nuclear-only color, staining confined to section edges, or staining over necrosis as suspect until it reproduces in intact cells and disappears in the no-primary control (standard IHC interpretation practice). Check cell identity: HPA reports High staining in heart muscle cardiomyocytes but Not detected in spleen red-pulp cells (HPA tissue IHC), while the selected product shows a spleen image without a stated fixative (A10510 tissue-IHC caption). Because HPA rates its tissue-IHC reliability Uncertain (HPA tissue IHC), resolve discordance with controls and independent validation.
Boster reagents
Best ARHGEF17 / Rho guanine nucleotide exchange factor 17 IHC Antibodies
A10510 has human IHC-P validation (catalog: applications IHC-P; reactivity Human) and a human spleen IHC image (A10510 image caption). No IF image is supplied (catalog: if_image_alts []).
Real IHC data
Anti-TEM4 ARHGEF17 Antibody
Cat # A10510
A10510 is listed for IHC-P in human samples (catalog: applications IHC-P; reactivity Human). Its IHC image shows human spleen at 2.5 μg/mL (A10510 image caption).
Which to pick: Choose A10510 for human paraffin-section IHC: it is a rabbit antibody with no reported clone, lists IHC-P, and shows human spleen staining at 2.5 μg/mL. The fixative is unreported (A10510 image caption). There is no validated IF/ICC or cross-species choice in this payload: A10510 gives an IF starting concentration of 20 μg/mL, but lists neither IF/ICC nor nonhuman reactivity and supplies no IF image (catalog: dilution_raw; applications; reactivity Human; if_image_alts []).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96PE2 (ARHGH_HUMAN, Rho guanine nucleotide exchange factor 17).
- Human Protein Atlas. ARHGEF17 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. ARHGEF17 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the plasma membrane..
- Human Protein Atlas. ARHGEF17 antibody validation summary (2 antibodies).
- Regulatory mechanism and prognostic value of sex hormone pathways connected with metabolism and immune signaling in clear cell renal cell carcinoma. Scientific reports 2025 — PMC12008239.
- A Robust Immunohistochemistry-Based Classification for BRAF V600E-Mutant Colorectal Cancer With Clinical Implications. Cancer science 2026 — PMC12775562.
- PubMed PMID:11559528 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF17 (Rho guanine nucleotide exchange factor 17). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10510 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Appendix. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10510); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARHGEF17, 2.5 μg/mL (datasheet A10510); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Staining–RNA consistency is medium (HPA tissue IHC); Isoform / epitope: No isoforms; one 1–2063 chain annotated (UniProt); Regulation: No expression regulator reported (UniProt). Evidence: UniProt Q96PE2, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the plasma…, Datasheet A10510, PMC12008239, PMC12775562. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF17/immunohistochemistry-ihc-guide.